Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel.

Trial Profile

Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2012

At a glance

  • Drugs Shigella flexneri 2A vaccine; Shigella sonnei vaccine
  • Indications Diarrhoea; Shigella infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2010 Results published in Vaccine.
    • 05 May 2009 Additional lead trial centre (Eunice Kennedy Shriver National Institute of Child Health and Human Development) added as reported by ClinicalTrials.gov.
    • 05 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top